Intravesical gemcitabine in recurrent superficial bladder carcinoma: Preliminary results on ablative efficacy and tolerability

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2381-2384

  Campodonico, Fabio ^a   Canepa, Giorgio ^a   Capponi, Giacomo ^a   Bozzo, Luigi ^a   Maffezzini, Massimo ^a  

^a GALLIERA HOSPITAL   (Italy)

Author keywords

Gemcitabine; Intravesical chemotherapy; Superficial bladder cancer

Indexed keywords

GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 22944457883     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maffezzini M, Audisio R, Pavone-Macaluso M and Hall RR: Bladder cancer. Crit Rev Oncol Hematol 27: 151-153, 1998.
2. Lamm DL, Van der Meijden PM, Morales A et al: Incidence and treatment of complication of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600, 1992.
3. Zincke H, Benson RC, Hilton JF et al: Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. J Urol 134: 1110-1114, 1985.
4. Lamm DL, Blumenstein BA, Crawford ED et al: A randomized trial intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205-1209, 1991.
5. Oosterlink W, Kurth KH, Schroder F et al: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149: 749-752, 1993.
6. Maffezzini M, Simonato A, Zanon M, Raber M and Carmignani G: Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol 155: 91-93, 1996.
7. Steinberg G, Bahnson R, Brosman S et al: Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163: 761-767, 2000.
8. Von der Maase H, Hansen SW, Roberts JT et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
9. Neri B, Doni L, Fulignati C, Gemelli MT et al: Gemcitabine plus epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. Anticancer Res 22: 2981-2984, 2002.
10. Culine S, Rebillard X, Iborra F et al: Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. Anticancer Res 23: 1903-1906, 2003.
11. Perabo FG, Lindner H, Schmidt D et al: Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines. Anticancer Res 23: 4805-4814, 2003.
12. Abbruzzese JL, Grunewald R and Weeks EA: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 18: 2780-2787, 2000.
13. Laufer M, Ramalingam S, Schoenberg MP et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 27: 697-703, 2003.
14. Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A and Schalken JA: Intravesical gemcitabine: a phase I pharmacokinetic study. Eur Urol 45: 182-186, 2004.
15. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW et al: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5: 2629-2637, 1999.
16. http://ctep.cancer.gov
17. Dalbagni G, Russo P, Sheinfeld J et al: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell- carcinoma of the bladder. J Clin Oncol 20: 3193-3198, 2002.
18. Benet LZ, Kroetz DL and Sheiner LB: Pharmacokinetics: the dynamics of drug absorption, distribution and elimination. In: The Pharmacological Basis of Therapeutics (Hanehman JG and Limbird LE, eds). New York, McGraw-Hill pp. 4-5, 1996.
19. Tizzani A, Gontero P, Casetta G et al: Intravesical gemcitabine in the treatment of intermediate risk superficial transitional cell carcinoma (TCC) of the bladder: a marker lesion study. Eur Urol 1(Suppl 2): 218, 2003 [Abstract LB12].
20. Van der Meijden APM, Hall RR, Pavone Macaluso M, Pawinsky A, Sylvester R and Van Glabbeke M: Marker tumor reponse to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superficial bladder tumors. Report from the European Organization for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 29: 199-203, 1996.